Indian Companies Ramping Up For Follow-On Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian pharma firms are expected to be active in filing for biosimilar approvals, Ranbaxy exec tells “The Pink Sheet” DAILY
You may also be interested in...
Dr. Reddy's Launches Rituxan Generic
Dr. Reddy's Laboratories launched the first follow-on biologic of the non-Hodgkin's lymphoma treatment rituximab on April 30, the company announced
Dr. Reddy’s Launches Rituxan Generic
Indian company plans to market Reditux in India at half the cost of Genentech/Biogen Idec’s Rituxan (rituximab).
Dr. Reddy’s Launches Rituxan Generic
Indian company plans to market Reditux in India at half the cost of Genentech/Biogen Idec’s Rituxan (rituximab).